SEC Form SC 13G filed by Allarity Therapeutics Inc.

8/29/24 3:57:47 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALLR alert in real time by email

SC 13G 1 allr13G.txt 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Allarity Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 016744401 (CUSIP Number) John Fife, 303 E Wacker Dr, Suite 1040 Chicago, IL 60601 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 19, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? Rule 13d-1(b) X Rule 13d-1(c) ? Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).? CUSIP No. 016744401 13G Page 2 of 8 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Streeterville Capital LLC 85-2954598 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Utah NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 8,999,800 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 2,114,737 (*) 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 8,999,800 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 14.7% (***) 12. TYPE OF REPORTING PERSON (see instructions) OO FOOTNOTES (*) The Series A Certificate of Designation precludes the reporting person from Submitting a conversion that would result in direct ownership in excess of 4.99% of the Issuer?s common stock. This 4.99% limit may be increased by request of the holder to 9.99% and will take effect on the 61st day of providing notice to the Issuer of such increase. In no event may a conversion cause the holder to directly own 9.99% of the common stock of the Issuer. (**) The dispositive power and voting power are calculated using 42,379,504 shares of common stock reported outstanding as of August 20, 2024 in the DEFR14A filed on the same date. (***) The beneficial ownership is calculated using a denominator of 60,908,504 which equal to the total voting power of the Issuer. 42,379,504 votes are allocated to the common stockholder and 18,529,000 are allocated to the holders of Series A Convertible Redeemable Preferred Stock. ? CUSIP No. 016744401 13G Page 3 of 8 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Streeterville Management LLC 85-3223919 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 8,999,800 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 2,114,737 (*) 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 8,999,800 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 14.7% (***) 12. TYPE OF REPORTING PERSON (see instructions) OO FOOTNOTES (*) The Series A Certificate of Designation precludes the reporting person from Submitting a conversion that would result in direct ownership in excess of 4.99% of the Issuer?s common stock. This 4.99% limit may be increased by request of the holder to 9.99% and will take effect on the 61st day of providing notice to the Issuer of such increase. In no event may a conversion cause the holder to directly own 9.99% of the common stock of the Issuer. (**) The dispositive power and voting power are calculated using 42,379,504 shares of common stock reported outstanding as of August 20, 2024 in the DEFR14A filed on the same date. (***) The beneficial ownership is calculated using a denominator of 60,908,504 which equal to the total voting power of the Issuer. 42,379,504 votes are allocated to the common stockholder and 18,529,000 are allocated to the holders of Series A Convertible Redeemable Preferred Stock. ? CUSIP No. 016744401 13G Page 4 of 8 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) John M. Fife 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION United States of America NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 8,999,800 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 2,114,737 (*) 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 8,999,800 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 14.7% (***) 12. TYPE OF REPORTING PERSON (see instructions) IN FOOTNOTES (*) The Series A Certificate of Designation precludes the reporting person from Submitting a conversion that would result in direct ownership in excess of 4.99% of the Issuer?s common stock. This 4.99% limit may be increased by request of the holder to 9.99% and will take effect on the 61st day of providing notice to the Issuer of such increase. In no event may a conversion cause the holder to directly own 9.99% of the common stock of the Issuer. (**) The dispositive power and voting power are calculated using 42,379,504 shares of common stock reported outstanding as of August 20, 2024 in the DEFR14A filed on the same date. (***) The beneficial ownership is calculated using a denominator of 60,908,504 which equal to the total voting power of the Issuer. 42,379,504 votes are allocated to the common stockholder and 18,529,000 are allocated to the holders of Series A Convertible Redeemable Preferred Stock. CUSIP No. 016744401 13G Page 5 of 8 Pages Item 1. (a) Name of Issuer Allarity Therapeutics, Inc. (b) Address of Issuer?s Principal Executive Offices 24 School Street, 2nd Floor Boston, MA 02108 Item 2. (a) Name of Person Filing This report is filed by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife with respect to the shares of Common Stock, $0.0001 par value per share, of the Issuer that are directly beneficially owned by Streeterville Capital LLC and indirectly beneficially owned by the other reporting and filing persons. (b) Address of the Principal Office or, if none, residence 303 East Wacker Drive, Suite 1040, Chicago, IL 60601 (c) Citizenship Streeterville Capital LLC is a Utah limited liability company. Streeterville Management LLC is a Utah limited liability company. John M. Fife is a United States citizen. (d) Title of Class of Securities Common Stock $0.0001 par value per share (e) CUSIP Number 016744401 Item 3. If this statement is filed pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) ? Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) ? Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) ? Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) ? Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) ? An investment adviser in accordance with ?240.13d-1(b)(1)(ii)(E); (f) ? An employee benefit plan or endowment fund in accordance with ?240.13d- 1(b)(1)(ii)(F); (g) ? A parent holding company or control person in accordance with ?240.13d- 1(b)(1)(ii)(G); (h) ? A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ? A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) ? Group, in accordance with ?240.13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 8,999,800 (b) Percent of class: 14.7% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 8,999,800 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 2,114,737 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ? . N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 016744401 13G Page 8 of 8 Pages After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 8/29/2024 Date Streeterville Capital LLC /s/ John Fife Signature John Fife/President Name/Title Streeterville Management LLC /s/ John Fife Signature John Fife/President Name/Title John M. Fife /s/ John Fife Signature John Fife Name/Title

Get the next $ALLR alert in real time by email

Date

Price Target

Rating

Analyst

7/28/2025

$9.00

Buy

Ascendiant Capital Markets

SEC Form SC 13G filed by Allarity Therapeutics Inc.

8/29/24 3:57:47 PM ET

$ALLR

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALLR alert in real time by email

Date

Price Target

Rating

Analyst

7/28/2025

$9.00

Buy

Ascendiant Capital Markets

SEC Form SC 13G filed by Allarity Therapeutics Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ALLR

SEC Form SC 13G filed by Allarity Therapeutics Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ALLR

$ALLR
Insider Trading

Officer Graff Jeremy R. converted options into 39,494 shares and covered exercise/tax liability with 14,613 shares (SEC Form 4)

SEC Form 3 filed by new insider Ervin Jeffrey S

Amendment: SEC Form 4 filed by Director Vazzano Joseph Walter

$ALLR
Analyst Ratings

Ascendiant Capital Markets initiated coverage on Allarity Therapeutics with a new price target

$ALLR
Press Releases

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

$ALLR
SEC Filings

SEC Form 10-Q filed by Allarity Therapeutics Inc.

SEC Form EFFECT filed by Allarity Therapeutics Inc.

SEC Form 424B3 filed by Allarity Therapeutics Inc.

$ALLR
Leadership Updates

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

Allarity Therapeutics Announces Changes to Board of Directors

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

$ALLR
Financials

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

$ALLR
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Allarity Therapeutics Inc.